Both AD 198 and PEP005 have been previously shown to induce the subcellular translocation of PKCδ in myeloid leukemia cells, which mediates the anti-leukemic effects of these two drugs [20,21,23,24]. This evidence concerns the gene PRKCD and myeloid leukemia.